GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (FRA:AP8) » Definitions » 3-Year EPS without NRI Growth Rate

Aptevo Therapeutics (FRA:AP8) 3-Year EPS without NRI Growth Rate : 35.20% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics 3-Year EPS without NRI Growth Rate?

Aptevo Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was €-12.84.

During the past 12 months, Aptevo Therapeutics's average EPS without NRI Growth Rate was -268.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 35.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Aptevo Therapeutics was 42.80% per year. The lowest was -2.10% per year. And the median was 26.50% per year.


Competitive Comparison of Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



Aptevo Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Aptevo Therapeutics  (FRA:AP8) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Aptevo Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics (FRA:AP8) Business Description

Industry
Traded in Other Exchanges
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics (FRA:AP8) Headlines

No Headlines